脂蛋白a [Lipoprotein a, Lp(a)]的结构与低密度脂蛋白类似,但其除了含载脂蛋白B-100以外,还含有一种糖蛋白载脂蛋白a与载脂蛋白B-100相连。流行病学、基因组学研究发现脂蛋白a升高与动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular disease, ASCVD)和主动脉瓣钙化发生具有因果关系。强化降脂治疗下,动脉粥样硬化性心血管疾病事件风险得到明显减低,但近年研究发现脂蛋白a升高已成为动脉粥样硬化性心血管事件的残余风险。因此现就脂蛋白a结构和其在心血管疾病发展中作用机制以及相关降低脂蛋白a治疗方法研究进展进行综述。
The structure of Lipoprotein a [Lp(a)] is similar to LDL, although it contains a kind of glycoprotein apolipoprotein a, which is attached to the apolipoprotein B-100, despite of apolipoprotein B-100. Epidemiological, genetic data indicate that Lp(a) is the cause for atherosclerotic cardiovascular dis-eases as well as calcification of the aortic valves. Though the risk of atherosclerotic cardiovascular disease (ASCVD) risk has been reduced as the result of intensive lipid-lowering therapy, the high level of Lp(a) has been the residual risk of ASCVD. Thus this review aims to outline the structure of Lp(a), its mechanism of the development of cardiovascular disease and the progress of therapies of lowering Lp(a).
脂蛋白a,动脉粥样硬化性心血管疾病,主动脉瓣狭窄,机制,治疗, Lipoprotein a Atherosclerotic Cardiovascular Disease Aortic Value Stenosis Mechanism Therapy摘要
脂蛋白a [Lipoprotein a, Lp(a)]的结构与低密度脂蛋白类似,但其除了含载脂蛋白B-100以外,还含有一种糖蛋白载脂蛋白a与载脂蛋白B-100相连。流行病学、基因组学研究发现脂蛋白a升高与动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular disease, ASCVD)和主动脉瓣钙化发生具有因果关系。强化降脂治疗下,动脉粥样硬化性心血管疾病事件风险得到明显减低,但近年研究发现脂蛋白a升高已成为动脉粥样硬化性心血管事件的残余风险。因此现就脂蛋白a结构和其在心血管疾病发展中作用机制以及相关降低脂蛋白a治疗方法研究进展进行综述。
关键词
脂蛋白a,动脉粥样硬化性心血管疾病,主动脉瓣狭窄,机制,治疗
Research Progress of Lipoprotein a in Cardiovascular Disease
Xingling Tan*, Jing Huang#
Department of Cardiology, Second Affiliated Hospital of Chongqing Medical University, Chongqing
The structure of Lipoprotein a [Lp(a)] is similar to LDL, although it contains a kind of glycoprotein apolipoprotein a, which is attached to the apolipoprotein B-100, despite of apolipoprotein B-100. Epidemiological, genetic data indicate that Lp(a) is the cause for atherosclerotic cardiovascular diseases as well as calcification of the aortic valves. Though the risk of atherosclerotic cardiovascular disease (ASCVD) risk has been reduced as the result of intensive lipid-lowering therapy, the high level of Lp(a) has been the residual risk of ASCVD. Thus this review aims to outline the structure of Lp(a), its mechanism of the development of cardiovascular disease and the progress of therapies of lowering Lp(a).
Keywords:Lipoprotein a, Atherosclerotic Cardiovascular Disease, Aortic Value Stenosis, Mechanism, Therapy
谭兴灵,黄 晶. 脂蛋白a在心血管疾病中的研究进展Research Progress of Lipoprotein a in Cardiovascular Disease[J]. 临床医学进展, 2023, 13(01): 272-279. https://doi.org/10.12677/ACM.2023.131042
参考文献ReferencesRoth, G.A., Mensah, G.A., Johnson, C.O., et al. (2020) Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study. Journal of the American College of Cardiology, 76, 2982-3021.
<br>https://doi.org/10.1016/j.jacc.2020.11.010Willeit, P., Ridker, P.M., Nestel, P.J., et al. (2018) Baseline and On-Statin Treatment Lipoprotein(a) Levels for Prediction of Cardiovascular Events: Individual Patient-Data Me-ta-Analysis of Statin Outcome Trials. The Lancet, 392, 1311- 1320. <br>https://doi.org/10.1016/S0140-6736(18)31652-0Wang, Z.W., Li, M., Li, J.J., et al. (2022) Association of Lipoprotein(a) with All-Cause and Cause-Specific Mortality: A Prospective Cohort Study. European Journal of Internal Medicine, 106, 63-70.
<br>https://doi.org/10.1016/j.ejim.2022.09.010van der Valk, F.M., Bekkering, S., Kroon, J., et al. (2016) Oxi-dized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation, 134, 611-624.
<br>https://doi.org/10.1161/CIRCULATIONAHA.116.020838Zheng, K.H., Tsimikas, S., Pawade, T., et al. (2019) Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients with Aortic Stenosis. Journal of the American College of Cardiology, 73, 2150-2162.
<br>https://doi.org/10.1016/j.jacc.2019.01.070Bourgeois, R., Bourgault, J., Despres, A.A., et al. (2021) Lipopro-tein Proteomics and Aortic Valve Transcriptomics Identify Biological Pathways Linking Lipoprotein(a) Levels to Aortic Stenosis. Metabolites, 11, 459.
<br>https://doi.org/10.3390/metabo11070459Salpeter, S.R., Walsh, J.M.E., Ormiston, T.M., et al. (2006) Me-ta-Analysis: Effect of Hormone-Replacement Therapy on Components of the Metabolic Syndrome in Postmenopausal Women. Diabetes Obesity & Metabolism, 8, 538-554.
<br>https://doi.org/10.1111/j.1463-1326.2005.00545.xOsnabrugge, R.L.J., Mylotte, D., Head, S.J., et al. (2013) Aortic Stenosis in the Elderly Disease Prevalence and Number of Candidates for Transcatheter Aortic Valve Replacement: A Meta-Analysis and Modeling Study. Journal of the American College of Cardiology, 62, 1002-1012. <br>https://doi.org/10.1016/j.jacc.2013.05.015Schmidt, K., Noureen, A., Kronenberg, F., et al. (2016) Thematic Review Series: Lipoprotein(a): Coming of Age at Last Structure, Function, and Genetics of Lipoprotein(a). Journal of Li-pid Research, 57, 1339-1359.
<br>https://doi.org/10.1194/jlr.R067314Lamina, C. and Kronenberg, F. (2013) The Mysterious Lipoprotein(a) Is Still Good for a Surprise. The Lancet Diabetes & Endocrinology, 1, 170-172. <br>https://doi.org/10.1016/S2213-8587(13)70085-8Jawi, M.M., Frohlich, J. and Chan, S.Y. (2020) Lipopro-tein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule. Journal of Lipids, 2020, Article ID: 3491764. <br>https://doi.org/10.1155/2020/3491764McCormick, S.P.A. and Schneider, W.J. (2019) Lipoprotein(a) Catabo-lism: A Case of Multiple Receptors. Pathology, 51, 155-164. <br>https://doi.org/10.1016/j.pathol.2018.11.003Brown, M.S. and Goldstein, J.L. (1986) A Receptor-Mediated Pathway for Cholesterol Homeostasis. Science, 232, 34-47. <br>https://doi.org/10.1126/science.3513311Romagnuolo, R., Scipione, C.A., Boffa, M.B., et al. (2015) Lipopro-tein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor. Journal of Biological Chemistry, 290, 11649-11662. <br>https://doi.org/10.1074/jbc.M114.611988Tam, S.P., Zhang, X. and Koschinsky, M.L. (1996) Interaction of a Recombinant Form of Apolipoprotein[a] with Human Fi-broblasts and with the Human Hepatoma Cell Line HepG2. Journal of Lipid Research, 37, 518-533.
<br>https://doi.org/10.1016/S0022-2275(20)37595-7Romagnuolo, R., Scipione, C.A., Marcovina, S.M., et al. (2017) Roles of the Low Density Lipoprotein Receptor and Related Receptors in Inhibition of Lipoprotein(a) Internaliza-tion by Proprotein Convertase Subtilisin/Kexin Type 9. PLOS ONE, 12, e0180869. <br>https://doi.org/10.1371/journal.pone.0180869Villard, E.F., Thedrez, A., Blankenstein, J., et al. (2016) PCSK9 Modulates the Secretion but Not the Cellular Uptake of Lipoprotein(a) ex Vivo: An Effect Blunted by Alirocumab. JACC: Basic to Translational Science, 1, 419-427.
<br>https://doi.org/10.1016/j.jacbts.2016.06.006Chemello, K., Beeske, S., Trang Tran, T.T., et al. (2020) Lipo-protein(a) Cellular Uptake ex Vivo and Hepatic Capture in Vivo Is Insensitive to PCSK9 Inhibition with Alirocumab. JACC: Basic to Translational Science, 5, 549-557.
<br>https://doi.org/10.1016/j.jacbts.2020.03.008Chemello, K., Garcia-Nafria, J., Gallo, A., et al. (2021) Lipopro-tein Metabolism in Familial Hypercholesterolemia. Journal of Lipid Research, 62, Article ID: 100062. <br>https://doi.org/10.1016/j.jlr.2021.100062Blom, D.J., Harada-Shiba, M., Rubba, P., et al. (2020) Efficacy and Safety of Alirocumab in Adults with Homozygous Familial Hypercholesterolemia: The Odyssey HoFH Trial. Journal of the American College of Cardiology, 76, 131-142.
<br>https://doi.org/10.1016/j.jacc.2020.05.027Croyal, M., Tran, T.T., Blanchard, R.H., et al. (2018) PCSK9 Inhi-bition with Alirocumab Reduces Lipoprotein(a) Levels in Nonhuman Primates by Lowering Apolipoprotein(a) Produc-tion Rate. Clinical Science, 132, 1075-1083.
<br>https://doi.org/10.1042/CS20180040Youssef, A., Clark, J.R., Marcovina, S.M., et al. (2022) Apo(a) and ApoB Interact Noncovalently within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion. Arteriosclerosis, Thrombosis, and Vascular Biology, 42, 289-304. <br>https://doi.org/10.1161/ATVBAHA.121.317335Watts, G.F., Chan, D.C., Pang, J., et al. (2020) PCSK9 Inhi-bition with Alirocumab Increases the Catabolism of Lipoprotein(a) Particles in Statin-Treated Patients with Elevated Lip-oprotein(a). Metabolism, 107, Article ID: 154221.
<br>https://doi.org/10.1016/j.metabol.2020.154221Yang, X.P., Amar, M.J., Vaisman, B., et al. (2013) Scavenger Receptor-BI Is a Receptor for Lipoprotein(a). Journal of Lipid Research, 54, 2450-2457. <br>https://doi.org/10.1194/jlr.M038877Hoekstra, M., Chen, H.Y., Rong, J., et al. (2021) Genome-Wide Associ-ation Study Highlights APOH as a Novel Locus for Lipoprotein(a) Levels-Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 41, 458-464.
<br>https://doi.org/10.1161/ATVBAHA.120.314965Croyal, M., Blanchard, V., Ouguerram, K., et al. (2020) VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly. Arteriosclerosis, Thrombosis, and Vascular Biology, 40, 819-829. <br>https://doi.org/10.1161/ATVBAHA.119.313877Capoulade, R., Torzewski, M., Mayr, M., et al. (2020) ApoCIII-Lp(a) Complexes in Conjunction with Lp(a)-OxPL Predict Rapid Progression of Aortic Stenosis. Heart, 106, 738-745. <br>https://doi.org/10.1136/heartjnl-2019-315840Hopewell, J.C., Haynes, R. and Baigent, C. (2018) The Role of Lipoprotein (a) in Chronic Kidney Disease. Journal of Lipid Research, 59, 577-585. <br>https://doi.org/10.1194/jlr.R083626Kamstrup, P.R., Tybjaerg-Hansen, A. and Nordestgaard, B.G. (2013) Ex-treme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction. Journal of the American College of Cardiol-ogy, 61, 1146-1156.
<br>https://doi.org/10.1016/j.jacc.2012.12.023Saeed, A. and Virani, S.S. (2018) Lipoprotein(a) and Cardiovascu-lar Disease: Current State and Future Directions for an Enigmatic Lipoprotein. Frontiers in Bioscience-Landmark, 23, 1099-1112. <br>https://doi.org/10.2741/4635Saeed, A., Sun, W.S., Agarwala, A., et al. (2019) Lipoprotein(a) Levels and Risk of Cardiovascular Disease Events in Individuals with Diabetes Mellitus or Prediabetes: The Atheroscle-rosis Risk in Communities Study. Atherosclerosis, 282, 52-56. <br>https://doi.org/10.1016/j.atherosclerosis.2018.12.022Erqou, S., Thompson, A., Di Angelantonio, E., et al. (2010) Apolipoprotein(a) Isoforms and the Risk of Vascular Disease Systematic Review of 40 Studies Involving 58,000 Participants. Journal of the American College of Cardiology, 55, 2160-2167. <br>https://doi.org/10.1016/j.jacc.2009.10.080Craig, W.Y., Neveux, L.M., Palomaki, G.E., et al. (1998) Lipopro-tein(a) as a Risk Factor for Ischemic Heart Disease: Meta-Analysis of Prospective Studies. Clinical Chemistry, 44, 2301-2306.
<br>https://doi.org/10.1093/clinchem/44.11.2301Binder, C.J., Papac-Milicevic, N. and Witztum, J.L. (2016) Innate Sensing of Oxidation-Specific Epitopes in Health and Disease. Nature Reviews Immunology, 16, 485-497. <br>https://doi.org/10.1038/nri.2016.63Di Fusco, S.A., Arca, M., Scicchitano, P., et al. (2022) Lipoprotein(a): A Risk Factor for Atherosclerosis and an Emerging Therapeutic Target. Heart, 109, 18-25. <br>https://doi.org/10.1136/heartjnl-2021-320708Di Gioia, M., Spreafico, R., Springstead, J.R., et al. (2020) En-dogenous Oxidized Phospholipids Reprogram Cellular Metabolism and Boost Hyperinflammation. Nature Immunology, 21, 42-53.
<br>https://doi.org/10.1038/s41590-019-0539-2Schnitzler, J.G., Hoogeveen, R.M., Ali, L., et al. (2020) Athero-genic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. Circulation Research, 126, 1346-1359.
<br>https://doi.org/10.1161/CIRCRESAHA.119.316206Boffa, M.B., Marar, T.T., Yeang, C., et al. (2019) Potent Reduction of Plasma Lipoprotein(a) with an Antisense Oligonucleotide in Human Subjects Does Not Affect ex Vivo Fi-brinolysis. Journal of Lipid Research, 60, 2082-2089.
<br>https://doi.org/10.1194/jlr.P094763Nordestgaard, B.G. and Langsted, A. (2016) Lipoprotein(a) as a Cause of Cardiovascular Disease: Insights from Epidemiology, Genetics, and Biology. Journal of Lipid Research, 57, 1953-1975. <br>https://doi.org/10.1194/jlr.R071233Di Maio, S., Lamina, C., Coassin, S., et al. (2022) Lipoprotein(a) and SARS-CoV-2 Infections: Susceptibility to Infections, Ischemic Heart Disease and Thromboembolic Events. Journal of Internal Medicine, 291, 101-107.
<br>https://doi.org/10.1111/joim.13338Enkhmaa, B., Petersen, K.S., Kris-Etherton, P.M., et al. (2020) Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)? Nutrients, 12, 2024. <br>https://doi.org/10.3390/nu12072024Bittner, V.A., Szarek, M., Aylward, P.E., et al. (2020) Effect of Aliro-cumab on Lipoprotein(a) and Cardiovascular Risk after Acute Coronary Syndrome. Journal of the American College of Cardiology, 75, 133-144.
<br>https://doi.org/10.1016/j.jacc.2019.10.057Koren, M.J., Moriarty, P.M., Baum, S.J., et al. (2022) Preclinical Development and Phase 1 Trial of a Novel siRNA Targeting Lipoprotein(a). Nature Medicine, 28, 96-103. <br>https://doi.org/10.1038/s41591-021-01634-wViney, N.J., van Capelleveen, J.C., Geary, R.S., et al. (2016) Antisense Oligonucleotides Targeting Apolipoprotein(a) in People with Raised Lipoprotein(a): Two Randomised, Dou-ble-Blind, Placebo-Controlled, Dose-Ranging Trials. The Lancet, 388, 2239-2253. <br>https://doi.org/10.1016/S0140-6736(16)31009-1Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., et al. (2020) Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. New England Journal of Medicine, 382, 244-255. <br>https://doi.org/10.1056/NEJMoa1905239Tsimikas, S., Gordts, P., Nora, C., et al. (2020) Satin Therapy Increases Lipoprotein(a) Levels. European Heart Journal, 41, 2275-2284. <br>https://doi.org/10.1093/eurheartj/ehz310Pokrovsky, S.N., Afanasieva, O.I. and Ezhov, M.V. (2020) Thera-peutic Apheresis for Management of Lp(a) Hyperlipoproteinemia. Current Atherosclerosis Reports, 22, 68. <br>https://doi.org/10.1007/s11883-020-00886-0Waldmann, E. and Parhofer, K.G. (2016) Lipoprotein Apheresis to Treat Elevated Lipoprotein(a). Journal of Lipid Research, 57, 1751-1757. <br>https://doi.org/10.1194/jlr.R056549Moriarty, P.M., Gray, J.V. and Gorby, L.K. (2019) Lipoprotein Apheresis for Lipoprotein(a) and Cardiovascular Disease. Journal of Clinical Lipidology, 13, 894-900. <br>https://doi.org/10.1016/j.jacl.2019.09.010Khan, T.Z., Hsu, L.Y., Arai, A.E., et al. (2017) Apheresis as Novel Treatment for Refractory Angina with Raised Lipoprotein(a): A Randomized Controlled Cross-Over Trial. European Heart Journal, 38, 1561-1569.
<br>https://doi.org/10.1093/eurheartj/ehx178Trinder, M., Paruchuri, K., Haidermota, S., et al. (2022) Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk. Journal of the American College of Cardiol-ogy, 79, 617-628.
<br>https://doi.org/10.1016/j.jacc.2021.11.055O’Donoghue, M.L., Fazio, S., Giugliano, R.P., et al. (2019) Lipo-protein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights from the FOURIER Trial. Circulation, 139, 1483-1492.
<br>https://doi.org/10.1161/CIRCULATIONAHA.118.037184Bergmark, B.A., O’Donoghue, M.L., Murphy, S.A., et al. (2020) An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Ste-nosis in the Fourier Trial. JAMA Cardiology, 5, 709-713.
<br>https://doi.org/10.1001/jamacardio.2020.0728Katzmann, J.L., Packard, C.J., Chapman, M.J., et al. (2020) Targeting RNA with Antisense Oligonucleotides and Small Interfering RNA JACC State-of-the-Art Review. Journal of the American College of Cardiology, 76, 563-579.
<br>https://doi.org/10.1016/j.jacc.2020.05.070Tsimikas, S., Viney, N.J., Hughes, S.G., et al. (2015) Antisense Therapy Targeting Apolipoprotein(a): A Randomised, Double-Blind, Placebo-Controlled Phase 1 Study. The Lancet, 386, 1472-1483.
<br>https://doi.org/10.1016/S0140-6736(15)61252-1Nissen, S.E., Wolski, K., Balog, C., et al. (2022) Single As-cending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals with Elevated Plasma Lipoprotein(a) Levels. Journal of the American Medical Association, 327, 1679-1687. <br>https://doi.org/10.1001/jama.2022.5050